Antioxidants vitamin E and 1-aminobenzotriazole prevent experimental non-alcoholic steatohepatitis in mice

References

• Paschos P, Paletas K. Non-alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009; 13: 9–19
   PubMed Web of Science ®Google Scholar
• Raszeja-Wyszomirska J, Lawniczak M, Marlicz W, Miezynska-Kurtycz J, Milkiewicz P. Non-alcoholic fatty liver disease: new view. Pol Merkur Lekarski 2008; 24: 568–71
   PubMedGoogle Scholar
• Day C, Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol 2002; 17(Suppl 3)S377–84
   PubMedGoogle Scholar
• Day CP, James OF. Steatohepatitis: a tale of two “hits”?. Gastroenterology 1998; 114: 842–5
   PubMed Web of Science ®Google Scholar
• Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:575–94, ix.
   PubMedGoogle Scholar
• Machado M, Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care 2006; 9: 637–42
   PubMed Web of Science ®Google Scholar
• Mitsuyoshi H, Itoh Y, Okanoue T. Role of oxidative stress in non-alcoholic steatohepatitis. Nippon Rinsho 2006; 64: 1077–82
   PubMedGoogle Scholar
• Kojima H, Sakurai S, Uemura M, Fukui H, Morimoto H, Tamagawa Y. Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis. Alcohol Clin Exp Res 2007; 31(suppl 1)S61–6
   PubMed Web of Science ®Google Scholar
• Nan YM, Wu WJ, Yao XX, Wang L. The role of apoptosis and the related genes in non-alcoholic steatohepatitis. Zhonghua Ganzangbing Zazhi 2007; 15: 41–6
   Google Scholar
• Farrell GC, Larter CZ, Hou JY, Zhang RH, Yeh MM, Williams J, et al. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. J Gastroenterol Hepatol 2009; 24: 443–52
   PubMed Web of Science ®Google Scholar
• Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437–43
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol 2005; 100: 1082–90
   Web of Science ®Google Scholar
• Beştaş A, Kahramanoglu M, Erhan OL, Bolat E, Ozercan I, Gürsu F, et al. The role of the antioxidants lycopene and vitamin E in the prevention of halothane-induced hepatotoxicity. Methods Find Exp Clin Pharmacol 2008; 30: 627–31
   PubMedGoogle Scholar
• Huang H, Chen Y, Ye J. Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E. Proc Natl Acad Sci USA 2007; 104: 18666–70
   PubMed Web of Science ®Google Scholar
• Nishiya T, Kato M, Suzuki T, Maru C, Kataoka H, Hattori C, et al. Involvement of cytochrome P450-mediated metabolism in tienilic acid hepatotoxicity in rats. Toxicol Lett 2008; 183: 81–9
   PubMed Web of Science ®Google Scholar
• Crincoli CM, Patel NN, Tchao R, Harvison PJ. Role of biotransformation in 3-(3, 5-dichlorophenyl)-2, 4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats. Toxicology 2008; 250: 100–8
   PubMed Web of Science ®Google Scholar
• Yu J, Ip E, Dela Peña A, Hou JY, Sesha J, Pera N, et al. COX-2 induction in mice with experimental nutritional steatohepatitis: role as pro-inflammatory mediator. Hepatology 2006; 43: 826–36
   PubMed Web of Science ®Google Scholar
• Paschos P, Paletas K. Non-alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009; 13: 9–19
   PubMed Web of Science ®Google Scholar
• Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 2009; 30: 88–96
   PubMed Web of Science ®Google Scholar
• Roberts EA, Yap J. Nonalcoholic fatty liver disease (NAFLD): approach in the adolescent patient. Curr Treat Options Gastroenterol 2006; 9: 423–31
   PubMedGoogle Scholar
• Di Sario A, Candelaresi C, Omenetti A, Benedetti A. Vitamin E in chronic liver diseases and liver fibrosis. Vitam Horm 2007; 76: 551–73
   PubMed Web of Science ®Google Scholar
• Machado MV, Ravasco P, Jesus L, Marques-Vidal P, Oliveira CR, Proença T, et al. Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet. Scand J Gastroenterol 2008; 43: 95–102
   PubMed Web of Science ®Google Scholar
• Mitsuyoshi H, Itoh Y, Okanoue T. Role of oxidative stress in non-alcoholic steatohepatitis. Nippon Rinsho 2006; 64: 1077–82
   PubMedGoogle Scholar
• Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99–112
   PubMed Web of Science ®Google Scholar
• Arvaniti VA, Thomopoulos KC, Tsamandas A, Makri M, Psyrogiannis A, Vafiadis G, et al. Serum adiponectin levels in different types of non alcoholic liver disease. Correlation with steatosis, necroinflammation and fibrosis. Acta Gastroenterol Belg 2008; 71: 355–60
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, De Iasio R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to disease severity. J Clin Endocrinol Metab 2005; 90: 3498–504
   PubMed Web of Science ®Google Scholar
• Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54: 117–21
   PubMed Web of Science ®Google Scholar
• Dela Pena A, Leclercq I, Field J, George J, Jones B, Farrell G. NF-κB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 2005; 129: 1663–74
   PubMed Web of Science ®Google Scholar
• Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 370–9
   PubMed Web of Science ®Google Scholar
• Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, Maruyama K, et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta-agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 2006; 536: 182–91
   PubMed Web of Science ®Google Scholar
• Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24: 3–20
   PubMed Web of Science ®Google Scholar
• Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 2004; 40: 46–54
   PubMed Web of Science ®Google Scholar
• Copaci I, Micu L, Voiculescu M. The role of cytokines in non-alcoholic steatohepatitis [review]. J Gastrointest Liver Dis 2006; 15: 363–73
   PubMedGoogle Scholar
• Shek FW, Benyon RC. How can transforming growth factor beta be targeted usefully to combat liver fibrosis?. Eur J Gastroenterol Hepatol6 2004; 16: 123–6
   PubMed Web of Science ®Google Scholar
• Gouville AC, Boullay V, Krysa G, Pilot J, Brusq JM, Loriolle F, et al. Inhibition of TGF-β signaling by an ALK5 Inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br J Pharmacol 2005; 145: 166–77
   PubMed Web of Science ®Google Scholar
• Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209–18
   PubMed Web of Science ®Google Scholar
• Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Ann Rev Pharmacol Toxicol 2005; 45: 605–28
   PubMed Web of Science ®Google Scholar
• Ribeiro PS, Cortez-Pinto H, Sola S, Castro RE, Ramalho RM, Baptista A, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004; 99: 1708–17
   PubMed Web of Science ®Google Scholar
• Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008; 134: 1641–54
   PubMed Web of Science ®Google Scholar
• Guicciardi ME, Gores GJ. Cheating death in the liver. Nat Med 2004; 10: 587–8
   PubMed Web of Science ®Google Scholar
• Ramalho RM, Cortez-Pinto H, Castro RE, Solá S, Costa A, Moura MC, et al. Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol 2006; 18: 21–9
   PubMed Web of Science ®Google Scholar
• Nan YM, Hu YL, Fu N, Wu WJ. Novel effect of the expression of proapoptotic proteins Bad, Bax and Bid in non-alcoholic steatohepatitis. Shijie Huaren Xiaohua Zazhi 2008; 16: 81–5
   Google Scholar
• Antonsson B. Mitochondria and the Bcl-2 family proteins in apoptosis signaling pathways. Mol Cell Biochem 2004; 256-257: 141–55
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta 1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15: 1667–72
   PubMed Web of Science ®Google Scholar
• Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136: 734–8
   PubMed Web of Science ®Google Scholar
• Kawanaka M, Mahmood S, Niiyama G, Izumi A, Kamei A, Ikeda H, et al. Control of oxidative stress and reduction in biochemical markers by vitamin E treatment in patients with nonalcoholic steatohepatitis: a pilot study. Hepatol Res 2004; 29: 39–41
   PubMed Web of Science ®Google Scholar
• Vajro P, Mandato C, Franzese A, Ciccimarra E, Lucariello S, Savoia M, et al. Vitamin treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr 2004; 38: 48–55
   PubMed Web of Science ®Google Scholar
• Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38: 413–9
   PubMed Web of Science ®Google Scholar
• Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 2485–90
   PubMed Web of Science ®Google Scholar